| 21:4.0.1.1.2.7.1.1 | SECTION 201.300
| 201.300 Notice to manufacturers, packers, and distributors of glandular preparations. | |
| 21:4.0.1.1.2.7.1.2 | SECTION 201.301
| 201.301 Notice to manufacturers, packers, and distributors of estrogenic hormone preparations. | |
| 21:4.0.1.1.2.7.1.3 | SECTION 201.302
| 201.302 Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil. | |
| 21:4.0.1.1.2.7.1.4 | SECTION 201.303
| 201.303 Labeling of drug preparations containing significant proportions of wintergreen oil. | |
| 21:4.0.1.1.2.7.1.5 | SECTION 201.304
| 201.304 Tannic acid and barium enema preparations. | |
| 21:4.0.1.1.2.7.1.6 | SECTION 201.305
| 201.305 Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings. | |
| 21:4.0.1.1.2.7.1.7 | SECTION 201.306
| 201.306 Potassium salt preparations intended for oral ingestion by man. | |
| 21:4.0.1.1.2.7.1.8 | SECTION 201.307
| 201.307 Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale. | |
| 21:4.0.1.1.2.7.1.9 | SECTION 201.308
| 201.308 Ipecac syrup; warnings and directions for use for over-the-counter sale. | |
| 21:4.0.1.1.2.7.1.10 | SECTION 201.309
| 201.309 Acetophenetidin (phenacetin)-containing preparations; necessary warning statement. | |
| 21:4.0.1.1.2.7.1.11 | SECTION 201.310
| 201.310 Phenindione; labeling of drug preparations intended for use by man. | |
| 21:4.0.1.1.2.7.1.12 | SECTION 201.311
| 201.311 [Reserved] | |
| 21:4.0.1.1.2.7.1.13 | SECTION 201.312
| 201.312 Magnesium sulfate heptahydrate; label declaration on drug products. | |
| 21:4.0.1.1.2.7.1.14 | SECTION 201.313
| 201.313 Estradiol labeling. | |
| 21:4.0.1.1.2.7.1.15 | SECTION 201.314
| 201.314 Labeling of drug preparations containing salicylates. | |
| 21:4.0.1.1.2.7.1.16 | SECTION 201.315
| 201.315 Over-the-counter drugs for minor sore throats; suggested warning. | |
| 21:4.0.1.1.2.7.1.17 | SECTION 201.316
| 201.316 Drugs with thyroid hormone activity for human use; required warning. | |
| 21:4.0.1.1.2.7.1.18 | SECTION 201.317
| 201.317 Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning. | |
| 21:4.0.1.1.2.7.1.19 | SECTION 201.319
| 201.319 Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions. | |
| 21:4.0.1.1.2.7.1.20 | SECTION 201.320
| 201.320 Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances. | |
| 21:4.0.1.1.2.7.1.21 | SECTION 201.323
| 201.323 Aluminum in large and small volume parenterals used in total parenteral nutrition. | |
| 21:4.0.1.1.2.7.1.22 | SECTION 201.325
| 201.325 Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required warnings and labeling information. | |
| 21:4.0.1.1.2.7.1.23 | SECTION 201.326
| 201.326 Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling. | |
| 21:4.0.1.1.2.7.1.24 | SECTION 201.327
| 201.327 Over-the-counter sunscreen drug products; required labeling based on effectiveness testing. | |
| 21:4.0.1.1.2.7.1.25 | SECTION 201.328
| 201.328 Labeling of medical gas containers. | |
| 21:4.0.1.1.2.7.1.26.1 | APPENDIX Appendix A
| Appendix A to Part 201 - Examples of Graphic Enhancements Used by FDA | |